Cargando…
Differences in Endothelial Activation and Dysfunction Induced by Antiphospholipid Antibodies Among Groups of Patients With Thrombotic, Refractory, and Non-refractory Antiphospholipid Syndrome
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by pregnancy morbidity or thrombosis and persistent antiphospholipid antibodies (aPL) that bind to the endothelium and induce endothelial activation, which is evidenced by the expression of adhesion molecules and the production...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8675389/ https://www.ncbi.nlm.nih.gov/pubmed/34925061 http://dx.doi.org/10.3389/fphys.2021.764702 |
_version_ | 1784615862630612992 |
---|---|
author | Velásquez, Manuela Peláez, Luisa F. Rojas, Mauricio Narváez-Sánchez, Raúl Velásquez, Jesús A. Escudero, Carlos San Martín, Sebastián Cadavid, Ángela P. |
author_facet | Velásquez, Manuela Peláez, Luisa F. Rojas, Mauricio Narváez-Sánchez, Raúl Velásquez, Jesús A. Escudero, Carlos San Martín, Sebastián Cadavid, Ángela P. |
author_sort | Velásquez, Manuela |
collection | PubMed |
description | Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by pregnancy morbidity or thrombosis and persistent antiphospholipid antibodies (aPL) that bind to the endothelium and induce endothelial activation, which is evidenced by the expression of adhesion molecules and the production of reactive oxygen species (ROS) and subsequent endothelial dysfunction marked by a decrease in the synthesis and release of nitric oxide (NO). These endothelial alterations are the key components for the development of severe pathological processes in APS. Patients with APS can be grouped according to the presence of other autoimmune diseases (secondary APS), thrombosis alone (thrombotic APS), pregnancy morbidity (obstetric APS), and refractoriness to conventional treatment regimens (refractory APS). Typically, patients with severe and refractory obstetric APS exhibit thrombosis and are classified as those having primary or secondary APS. The elucidation of the mechanisms underlying these alterations according to the different groups of patients with APS could help establish new therapies, particularly necessary for severe and refractory cases. Therefore, this study aimed to evaluate the differences in endothelial activation and dysfunction induced by aPL between patients with refractory obstetric APS and other APS clinical manifestations. Human umbilical vein endothelial cells (HUVECs) were stimulated with polyclonal immunoglobulin-G (IgG) from different groups of patients n = 21), including those with primary (VTI) and secondary thrombotic APS (VTII) and refractory primary (RI+), refractory secondary (RII+), and non-refractory primary (NR+) obstetric APS. All of them with thrombosis. The expression of adhesion molecules; the production of ROS, NO, vascular endothelial growth factor (VEGF), and endothelin-1; and the generation of microparticles were used to evaluate endothelial activation and dysfunction. VTI IgG induced the expression of adhesion molecules and the generation of microparticles and VEGF. RI+ IgG induced the expression of adhesion molecules and decreased NO production. RII+ IgG increased the production of microparticles, ROS, and endothelin-1 and reduced NO release. NR+ IgG increased the production of microparticles and endothelin-1 and decreased the production of VEGF and NO. These findings reveal differences in endothelial activation and dysfunction among groups of patients with APS, which should be considered in future studies to evaluate new therapies, especially in refractory cases. |
format | Online Article Text |
id | pubmed-8675389 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86753892021-12-17 Differences in Endothelial Activation and Dysfunction Induced by Antiphospholipid Antibodies Among Groups of Patients With Thrombotic, Refractory, and Non-refractory Antiphospholipid Syndrome Velásquez, Manuela Peláez, Luisa F. Rojas, Mauricio Narváez-Sánchez, Raúl Velásquez, Jesús A. Escudero, Carlos San Martín, Sebastián Cadavid, Ángela P. Front Physiol Physiology Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by pregnancy morbidity or thrombosis and persistent antiphospholipid antibodies (aPL) that bind to the endothelium and induce endothelial activation, which is evidenced by the expression of adhesion molecules and the production of reactive oxygen species (ROS) and subsequent endothelial dysfunction marked by a decrease in the synthesis and release of nitric oxide (NO). These endothelial alterations are the key components for the development of severe pathological processes in APS. Patients with APS can be grouped according to the presence of other autoimmune diseases (secondary APS), thrombosis alone (thrombotic APS), pregnancy morbidity (obstetric APS), and refractoriness to conventional treatment regimens (refractory APS). Typically, patients with severe and refractory obstetric APS exhibit thrombosis and are classified as those having primary or secondary APS. The elucidation of the mechanisms underlying these alterations according to the different groups of patients with APS could help establish new therapies, particularly necessary for severe and refractory cases. Therefore, this study aimed to evaluate the differences in endothelial activation and dysfunction induced by aPL between patients with refractory obstetric APS and other APS clinical manifestations. Human umbilical vein endothelial cells (HUVECs) were stimulated with polyclonal immunoglobulin-G (IgG) from different groups of patients n = 21), including those with primary (VTI) and secondary thrombotic APS (VTII) and refractory primary (RI+), refractory secondary (RII+), and non-refractory primary (NR+) obstetric APS. All of them with thrombosis. The expression of adhesion molecules; the production of ROS, NO, vascular endothelial growth factor (VEGF), and endothelin-1; and the generation of microparticles were used to evaluate endothelial activation and dysfunction. VTI IgG induced the expression of adhesion molecules and the generation of microparticles and VEGF. RI+ IgG induced the expression of adhesion molecules and decreased NO production. RII+ IgG increased the production of microparticles, ROS, and endothelin-1 and reduced NO release. NR+ IgG increased the production of microparticles and endothelin-1 and decreased the production of VEGF and NO. These findings reveal differences in endothelial activation and dysfunction among groups of patients with APS, which should be considered in future studies to evaluate new therapies, especially in refractory cases. Frontiers Media S.A. 2021-12-02 /pmc/articles/PMC8675389/ /pubmed/34925061 http://dx.doi.org/10.3389/fphys.2021.764702 Text en Copyright © 2021 Velásquez, Peláez, Rojas, Narváez-Sánchez, Velásquez, Escudero, San Martín and Cadavid. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Physiology Velásquez, Manuela Peláez, Luisa F. Rojas, Mauricio Narváez-Sánchez, Raúl Velásquez, Jesús A. Escudero, Carlos San Martín, Sebastián Cadavid, Ángela P. Differences in Endothelial Activation and Dysfunction Induced by Antiphospholipid Antibodies Among Groups of Patients With Thrombotic, Refractory, and Non-refractory Antiphospholipid Syndrome |
title | Differences in Endothelial Activation and Dysfunction Induced by Antiphospholipid Antibodies Among Groups of Patients With Thrombotic, Refractory, and Non-refractory Antiphospholipid Syndrome |
title_full | Differences in Endothelial Activation and Dysfunction Induced by Antiphospholipid Antibodies Among Groups of Patients With Thrombotic, Refractory, and Non-refractory Antiphospholipid Syndrome |
title_fullStr | Differences in Endothelial Activation and Dysfunction Induced by Antiphospholipid Antibodies Among Groups of Patients With Thrombotic, Refractory, and Non-refractory Antiphospholipid Syndrome |
title_full_unstemmed | Differences in Endothelial Activation and Dysfunction Induced by Antiphospholipid Antibodies Among Groups of Patients With Thrombotic, Refractory, and Non-refractory Antiphospholipid Syndrome |
title_short | Differences in Endothelial Activation and Dysfunction Induced by Antiphospholipid Antibodies Among Groups of Patients With Thrombotic, Refractory, and Non-refractory Antiphospholipid Syndrome |
title_sort | differences in endothelial activation and dysfunction induced by antiphospholipid antibodies among groups of patients with thrombotic, refractory, and non-refractory antiphospholipid syndrome |
topic | Physiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8675389/ https://www.ncbi.nlm.nih.gov/pubmed/34925061 http://dx.doi.org/10.3389/fphys.2021.764702 |
work_keys_str_mv | AT velasquezmanuela differencesinendothelialactivationanddysfunctioninducedbyantiphospholipidantibodiesamonggroupsofpatientswiththromboticrefractoryandnonrefractoryantiphospholipidsyndrome AT pelaezluisaf differencesinendothelialactivationanddysfunctioninducedbyantiphospholipidantibodiesamonggroupsofpatientswiththromboticrefractoryandnonrefractoryantiphospholipidsyndrome AT rojasmauricio differencesinendothelialactivationanddysfunctioninducedbyantiphospholipidantibodiesamonggroupsofpatientswiththromboticrefractoryandnonrefractoryantiphospholipidsyndrome AT narvaezsanchezraul differencesinendothelialactivationanddysfunctioninducedbyantiphospholipidantibodiesamonggroupsofpatientswiththromboticrefractoryandnonrefractoryantiphospholipidsyndrome AT velasquezjesusa differencesinendothelialactivationanddysfunctioninducedbyantiphospholipidantibodiesamonggroupsofpatientswiththromboticrefractoryandnonrefractoryantiphospholipidsyndrome AT escuderocarlos differencesinendothelialactivationanddysfunctioninducedbyantiphospholipidantibodiesamonggroupsofpatientswiththromboticrefractoryandnonrefractoryantiphospholipidsyndrome AT sanmartinsebastian differencesinendothelialactivationanddysfunctioninducedbyantiphospholipidantibodiesamonggroupsofpatientswiththromboticrefractoryandnonrefractoryantiphospholipidsyndrome AT cadavidangelap differencesinendothelialactivationanddysfunctioninducedbyantiphospholipidantibodiesamonggroupsofpatientswiththromboticrefractoryandnonrefractoryantiphospholipidsyndrome |